Abstracts tagged "adalimumab and methotrexate (MTX)"

Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Naonobu Sugiyama ³, Noriko Iikuni ⁴, Koshika Soma ⁵, Harry Shi ⁶, Eduardo Mysler ⁷, Robert J. Moots ⁸, Josef Smolen ⁹ and Roy Fleischmann ¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…
Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting
Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)
Arthur Kavanaugh¹, Ronald F van Vollenhoven², Prashanth Sunkureddi³, Ying Zhang⁴, Jessica L. Suboticki⁵ and Josef S. Smolen⁶, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³University of Texas Medical Branch, Galveston, TX, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Mettawa, IL, ⁶Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…
Abstract Number: 593 • 2016 ACR/ARHP Annual Meeting
Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate
Josef S. Smolen¹, Ronald F. van Vollenhoven², Benjamin A. Wolfe³, Su Chen³, Jessica L. Suboticki³ and Arthur Kavanaugh⁴, ¹Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria, ²Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA
Background/Purpose: In patients (pts) with early rheumatoid arthritis (RA), conventional synthetic DMARDs (csDMARDs), preferably methotrexate (MTX), are recommended as first line therapy.1,2 For pts who…
Abstract Number: 640 • 2016 ACR/ARHP Annual Meeting
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate
Gurjit S. Kaeley¹, Veena K. Ranganath², Daryl K. MacCarter³, Aileen L. Pangan⁴, Xin Wang⁴ and Jasmina Kalabic⁵, ¹University of Florida, Jacksonville, FL, ²University of California at Los Angeles, Los Angeles, CA, ³North Valley Hospital, Whitefish, MT, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Obese rheumatoid arthritis (RA) patients (pts) may have higher levels of inflammatory mediators, greater joint swelling and tenderness, and suboptimal response to therapy. We…